Although the recall responses to MHV-68 induced more effector molecule production (GzmB+IFN-γ+) in the engineered cells, the EμMyc B cell lymphoma challenge showed worse tumor protection with larger tumors and shorter survival time in recipients of the engineered cells. The gene discussed is GZMB; the disease is B-cell non-Hodgkin lymphoma.